WO2009143292A9 - Procédé de traitement d'une pneumoconiose par des oligodésoxynucléotides - Google Patents

Procédé de traitement d'une pneumoconiose par des oligodésoxynucléotides Download PDF

Info

Publication number
WO2009143292A9
WO2009143292A9 PCT/US2009/044739 US2009044739W WO2009143292A9 WO 2009143292 A9 WO2009143292 A9 WO 2009143292A9 US 2009044739 W US2009044739 W US 2009044739W WO 2009143292 A9 WO2009143292 A9 WO 2009143292A9
Authority
WO
WIPO (PCT)
Prior art keywords
oligodeoxynucleotides
treating pneumoconiosis
pneumoconiosis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044739
Other languages
English (en)
Other versions
WO2009143292A2 (fr
Inventor
Dennis M. Klinman
Takashi Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US12/993,809 priority Critical patent/US8222225B2/en
Priority to EP09751520A priority patent/EP2278979A4/fr
Publication of WO2009143292A2 publication Critical patent/WO2009143292A2/fr
Publication of WO2009143292A9 publication Critical patent/WO2009143292A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2009/044739 2008-05-21 2009-05-20 Procédé de traitement d'une pneumoconiose par des oligodésoxynucléotides Ceased WO2009143292A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/993,809 US8222225B2 (en) 2008-05-21 2009-05-20 Method of treating pneumoconiosis with oligodeoxynucleotides
EP09751520A EP2278979A4 (fr) 2008-05-21 2009-05-20 Procédé de traitement d'une pneumoconiose par des oligodésoxynucléotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5510208P 2008-05-21 2008-05-21
US61/055,102 2008-05-21

Publications (2)

Publication Number Publication Date
WO2009143292A2 WO2009143292A2 (fr) 2009-11-26
WO2009143292A9 true WO2009143292A9 (fr) 2010-03-04

Family

ID=41340870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044739 Ceased WO2009143292A2 (fr) 2008-05-21 2009-05-20 Procédé de traitement d'une pneumoconiose par des oligodésoxynucléotides

Country Status (3)

Country Link
US (1) US8222225B2 (fr)
EP (1) EP2278979A4 (fr)
WO (1) WO2009143292A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
AU4343700A (en) * 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
EP1404873B1 (fr) * 2001-06-21 2013-05-22 Dynavax Technologies Corporation Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
AU2003263963A1 (en) * 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
CA2503693A1 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
WO2010067262A1 (fr) * 2008-12-09 2010-06-17 Pfizer Inc. Oligonucléotides immunostimulants
RU2597157C1 (ru) * 2015-09-15 2016-09-10 Федеральное бюджетное учреждение науки "Екатеринбургский медицинский-научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ повышения устойчивости организма к хроническому комбинированному токсическому действию наночастиц оксида никеля и оксида марганца
EP3468605A4 (fr) 2016-06-08 2020-01-08 President and Fellows of Harvard College Vecteur viral modifié réduisant l'induction de réponses inflammatoires et immunitaires
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
WO1983001451A1 (fr) 1981-10-23 1983-04-28 Molecular Biosystems Inc Agent therapeutique d'oligonucleotide et ses procedes de fabrication
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US6288042B1 (en) * 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1995026204A1 (fr) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (fr) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US7094766B1 (en) * 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1998037919A1 (fr) 1997-02-28 1998-09-03 University Of Iowa Research Foundation UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
AU2002353783A1 (en) * 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
AU2003263963A1 (en) * 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
JP2005538186A (ja) * 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
US7514412B2 (en) * 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
CA2565714C (fr) * 2004-05-06 2014-12-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Processus et compositions pour le traitement de l'uveite
US7226906B2 (en) * 2004-08-16 2007-06-05 Array Biopharma, Inc. Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides

Also Published As

Publication number Publication date
WO2009143292A2 (fr) 2009-11-26
US20110077289A1 (en) 2011-03-31
EP2278979A2 (fr) 2011-02-02
US8222225B2 (en) 2012-07-17
EP2278979A4 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
WO2010042548A9 (fr) Procédés de traitement de l'inflammation
IL212348A0 (en) Treatment method
WO2009129357A9 (fr) Traitement de la dysérection
EP2351872A4 (fr) Procédé de traitement utilisant du plasma
EP2340254B8 (fr) Compositions et procédés pour traiter l épilepsie
AU2013204721A1 (en) Methods for treating cachexia
WO2010080603A9 (fr) Procédé de traitement d'une agressivité
IL202002A0 (en) Method of treating diabetes
EP2299815A4 (fr) Procédé de traitement de brûlures mettant en oeuvre un composé d avermectine
ZA201007680B (en) Method of treating metalliferrous materials
AU2008904356A0 (en) Method of Treatment
AU2008904478A0 (en) Method of treatment
AU2008902659A0 (en) Method of Treatment
AU2008900291A0 (en) Method of treatment
AU2008903259A0 (en) Method of treatment
HK1141223A (en) Method of treating diabetes
AU2007903139A0 (en) Method of treatment
AU2007900278A0 (en) Method of treatment
AU2008902372A0 (en) Methods of treatment
HK1158228A (en) Methods of treating inflammation
HK1146810A (zh) 炎症治療方法
AU2008901249A0 (en) Method of treatment and uses therefor
AU2006900254A0 (en) Method of treating carpet
AU2006900253A0 (en) Method of treating carpet
AU2008902088A0 (en) A method of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751520

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12993809

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009751520

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE